Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
DURHAM, N.C., May 02, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that it will host a live conference call and audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 3258363. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
